• Home
• Menu
  • JOIN
  • SI Premium
  • Ratings
  • Mergers
  • Earnings
  • Dividends
  • IPOs
  • Hedge Funds
  • Premium Letters
  • Send a Tip
  • API/Data
• JOIN
• SI Premium
  • Full Feed View
  • Headline View
  • SI Premium Squawk Box
  • Alerts
  • Custom Headlines
  • Upgrade Your Current Account
  • API
• Calendars
  • Co. NDR/Event Calendar
  • Dividend Calendar
  • Earnings Calendar
  • Event Driven
  • FDA Calendar
  • Investor Conferences
  • IPO Calendar
  • Merger Arb
  • Ratings Calendar
  • Stock Split Calendar
• Ratings
  • Analyst Comments
  • Hot Analyst Comments
  • Analyst EPS Change
  • Analyst EPS View
  • Analyst PT Change
  • Credit Ratings
  • Downgrade News
  • Hot Downgrades
  • New Coverage News
  • Hot New Coverage
  • Upgrade News
  • Hot Upgrades
  • More...
• Mergers
  • Merger News
  • Hot M&A News
  • Private Equity
  • Rumors
  • SPAC News
  • Spinoffs
  • Merger Arbitrage
  • Event Driven
  • 2021 Top M&A Deals
  • Top 50 Takeover Targets
  • More...
• Earnings
  • Earnings Calendar
  • Earnings News
  • Hot Earnings
  • Guidance
  • Hot Guidance
  • Conference Calls
  • Earnings History Search
  • More...
• Dividends
  • Dividend Calendar
  • Dividend News
  • Hot Dividends
  • Dividend Hike
  • Special Dividends
  • Stock Buybacks
  • Hot Stock Buybacks
  • Stock Splits
  • More...
• IPOs
  • IPO News
  • Hot IPOs
  • Equity Offerings
  • Recent IPOs
  • Upcoming IPOs
  • 2021 Top IPOs
  • More...
• Hedge Funds
  • 13D
  • 13F
  • 13G
  • Hedge Funds News
  • Hot Insider Trades
  • Insider Trades
  • More...
• Premium Letters
  • Pulse Picks
  • Stealth Growth Insider
• Send a Tip
• API/Data

• QUICK LINKS :
• Goldman Sachs Conviction Buy List
• Warren Buffett News
• Elliott Management News
• Follow @Street_Insider

Opexa Therapeutics (OPXA) Enters Development Agreement with Merck Serono Worth Up to $225M